Table 2 Clinical outcomes
From: A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis
Case | Pre-sirolimus BCVA | Post-sirolimus BCVA | Clinical course | Corticosteroid requirement | Clinical outcome | Current therapy |
|---|---|---|---|---|---|---|
1 | OD–20/50 | OD–20/25 | Resolution with sirolimus 2 mg/day | Did not require prednisone | Decreased inflammation | Sirolimus 2 mg/day |
OS–20/25 | OS–20/20 | Decreased flare rate | ||||
2 | OD–20/30 | OD–20/15 | Initial improvement with a flare 5 weeks after starting sirolimus | 40 to 5 mg/day with sirolimus/MTX combination | Decreased inflammation | Sirolimus 3 mg/day |
OS–20/30 | OS–20/20 | No additional flares after adding MTX | Decreased flare rate | MTX 20 mg/week | ||
Prednisone 5 mg/day | ||||||
3 | OD–20/150 | OD–20/25 | No initial improvement with sirolimus 2 mg/day | 40 to 5 mg/day with sirolimus/MTX combination. | Decreased inflammation, decreased flare rate | Sirolimus 4 mg/day |
Increased to 4 mg/day and restarted MTX 10 mg/week with resolution of CME | MTX 10 mg/week | |||||
Prednisone 5 mg/day | ||||||
4 | OD–20/25 | OD–20/20 | Improvement with the addition of sirolimus 3 mg/day to MTX 25 mg/week | 10 mg/day to tapered off | Decreased inflammation | Sirolimus 3 mg/day |
OS–20/25 | OS–20/20 | Decreased flare rate | MTX 25 mg/week | |||
5 | OD–20/20 | OD–20/15 | Improvement with sirolimus 3 mg/day and cyclosporine 50 mg BID | 20 to 10 mg/day while on sirolimus | Failure due to side effects | Cyclosporine 100 mg BID |
Sirolimus was stopped after the patient developed a DVT | Prednisone 20 mg/day | |||||
6 | OD–20/30 | OD–20/25 | Initial improvement of vision but sirolimus was stopped due to a recurrence of aseptic meningitis | Not enough data | Failure due to side effects | Prednisone 20 mg/day |
OS–20/30 | OS–20/20 | |||||
7 | OD–20/60 | No data | Platelet count dropped from 160,000 to 80,000 after starting sirolimus | Not enough data | Failure due to side effects | Prednisone 20 mg/day |
OS–20/50 | Sirolimus was stopped and the platelets rebounded | |||||
8 | OD–20/150 | No data | Missed several follow-up appointments | No data | Lost to follow-up | No data |
OS–10/100 |